Demonising Justin Gatlin
13th September 2015
USADA announced today that UFC® athlete, Nick Roehrick, of Denver, Colo., has tested positive for a prohibited substance and accepted the maximum one-year sanction for his anti-doping policy violation. Roehrick, 30, tested positive for clomiphene and its metabolite, 4-hydroxyclomiphene, following an out-of-competition urine test conducted on August 8, 2017. Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency Prohibited List.
Clomiphene is not approved by the U.S. Food & Drug Administration (FDA) for use in the male population, meaning such off-label clinical use has not been thoroughly studied for safety and efficacy. Clomiphene also indirectly promotes the secretion of testosterone. Increasing testosterone, especially when combined with strength training, has been demonstrated to increase fat-free mass, muscle size, and strength in males, potentially leading to performance enhancement in sport.
Roehrick’s one-year period of ineligibility, the highest sanction for a first offense involving a Specified Substance, began on August 17, 2017, the date his provisional suspension was imposed. Pursuant to the UFC Anti-Doping Policy, all UFC athletes serving a period of ineligibility for an anti-doping policy violation are required to remain in the USADA registered testing pool and make themselves available for testing in order to receive credit for time completed under his or her sanction.
• This media release was originally published by the US Anti-Doping Agency (USADA) and the Ultimate Fighting Championships on 21 September 2017. To access the original, please click here.
In 2011, when he was just 16, William Brothers was named as Canadian Youth Swimmer...
The movement for credible cycling (MPCC) has branded the World Anti-Doping Agency’s (WADA) answer to...
The World Anti-Doping Agency (WADA) announces that the Agency’s Foundation Board Meeting will be held on 16 November...